Published in Expert Opin Drug Deliv on July 18, 2014
Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle. Expert Opin Biol Ther (2016) 0.85
Ultrasonic Nanobubbles Carrying Anti-PSMA Nanobody: Construction and Application in Prostate Cancer-Targeted Imaging. PLoS One (2015) 0.79
N-Succinimidyl 3-((4-(4-[(18)F]fluorobutyl)-1H-1,2,3-triazol-1-yl)methyl)-5-(guanidinomethyl)benzoate ([(18)F]SFBTMGMB): a residualizing label for (18)F-labeling of internalizing biomolecules. Org Biomol Chem (2015) 0.78
Preclinical Evaluation of 18F-Labeled Anti-HER2 Nanobody Conjugates for Imaging HER2 Receptor Expression by Immuno-PET. J Nucl Med (2016) 0.76
Distinct antibody species: structural differences creating therapeutic opportunities. Curr Opin Immunol (2016) 0.76
In vivo detection of small tumour lesions by multi-pinhole SPECT applying a (99m)Tc-labelled nanobody targeting the Epidermal Growth Factor Receptor. Sci Rep (2016) 0.75
Camelid Single-Domain Antibodies As an Alternative to Overcome Challenges Related to the Prevention, Detection, and Control of Neglected Tropical Diseases. Front Immunol (2017) 0.75
Molecular dynamics simulations and docking enable to explore the biophysical factors controlling the yields of engineered nanobodies. Sci Rep (2016) 0.75
Predicting the response to CTLA-4 blockade by longitudinal noninvasive monitoring of CD8 T cells. J Exp Med (2017) 0.75
Improved survival in multiple myeloma and the impact of novel therapies. Blood (2007) 12.70
Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med (1994) 8.39
Naturally occurring antibodies devoid of light chains. Nature (1993) 7.35
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer (2011) 6.44
The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev (2010) 5.26
Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov (2008) 4.32
A synthetic IgG-binding domain based on staphylococcal protein A. Protein Eng (1989) 3.31
Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. J Clin Oncol (2006) 2.57
Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res (1999) 1.92
Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains. Protein Eng (1994) 1.85
Engineered antibodies. Nat Med (2003) 1.84
Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results. J Clin Oncol (2005) 1.83
Preliminary evaluation of (177)Lu-labeled knottin peptides for integrin receptor-targeted radionuclide therapy. Eur J Nucl Med Mol Imaging (2010) 1.75
New insights on cell death from radiation exposure. Lancet Oncol (2005) 1.72
Nanobodies targeting mouse/human VCAM1 for the nuclear imaging of atherosclerotic lesions. Circ Res (2012) 1.67
Comparison of llama VH sequences from conventional and heavy chain antibodies. Mol Immunol (1998) 1.67
Cholecystokinin(CCK)-A and CCK-B/gastrin receptors in human tumors. Cancer Res (1997) 1.64
General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold. J Biol Chem (2008) 1.60
Isolation of antigen specific llama VHH antibody fragments and their high level secretion by Saccharomyces cerevisiae. J Biotechnol (2000) 1.58
Efficient targeting of conserved cryptic epitopes of infectious agents by single domain antibodies. African trypanosomes as paradigm. J Biol Chem (2003) 1.54
Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size. Cancer Res (2010) 1.51
Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT. J Nucl Med (2008) 1.45
Translocation of HIV TAT peptide and analogues induced by multiplexed membrane and cytoskeletal interactions. Proc Natl Acad Sci U S A (2011) 1.42
Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule. Cancer Res (2007) 1.40
Engineered knottin peptides: a new class of agents for imaging integrin expression in living subjects. Cancer Res (2009) 1.38
Gelatin-based plasma expander effectively reduces renal uptake of 111In-octreotide in mice and rats. J Nucl Med (2006) 1.37
Efficient tumor targeting by single-domain antibody fragments of camels. Int J Cancer (2002) 1.36
Renal uptake of radiolabeled octreotide in human subjects is efficiently inhibited by succinylated gelatin. J Nucl Med (2006) 1.34
Indication for different mechanisms of kidney uptake of radiolabeled peptides. J Nucl Med (2007) 1.31
Trial Watch: Anticancer radioimmunotherapy. Oncoimmunology (2013) 1.31
Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med (2002) 1.30
In vitro identification of vasoactive intestinal peptide receptors in human tumors: implications for tumor imaging. J Nucl Med (1995) 1.25
Lutetium-labelled peptides for therapy of neuroendocrine tumours. Eur J Nucl Med Mol Imaging (2012) 1.25
Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology. Mol Cancer Ther (2008) 1.24
Albumin as a versatile platform for drug half-life extension. Biochim Biophys Acta (2013) 1.23
Functional heavy-chain antibodies in Camelidae. Adv Immunol (2001) 1.22
Nanobody-based targeting of the macrophage mannose receptor for effective in vivo imaging of tumor-associated macrophages. Cancer Res (2012) 1.20
A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth. Int J Cancer (2011) 1.16
Prokaryotic expression of antibodies. Cancer Metastasis Rev (2005) 1.15
Antibodies to watch in 2014. MAbs (2013) 1.14
Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. J Clin Oncol (2006) 1.12
Clinical radioimmunotherapy--the role of radiobiology. Nat Rev Clin Oncol (2011) 1.10
Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer. FASEB J (2011) 1.08
Nanobodies as tools for in vivo imaging of specific immune cell types. J Nucl Med (2010) 1.07
Pharmacokinetics and imaging of 212Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian cancer patients. Cancer Biother Radiopharm (2013) 1.05
The benefits and risks of I-131 therapy in patients with well-differentiated thyroid cancer. Thyroid (2009) 1.05
Radioimmunotherapy of lymphoma: Bexxar and Zevalin. Semin Nucl Med (2010) 1.04
Induced refolding of a temperature denatured llama heavy-chain antibody fragment by its antigen. Proteins (2005) 1.04
Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 Nanobodies for iPET imaging of HER2 receptor expression in cancer. J Nucl Med (2013) 1.03
Biodistribution of 211At labeled HER-2 binding affibody molecules in mice. Oncol Rep (2007) 1.02
Antigen binding and solubility effects upon the veneering of a camel VHH in framework-2 to mimic a VH. J Mol Biol (2005) 1.02
In vitro analysis and in vivo tumor targeting of a humanized, grafted nanobody in mice using pinhole SPECT/micro-CT. J Nucl Med (2010) 0.99
SPECT imaging of joint inflammation with Nanobodies targeting the macrophage mannose receptor in a mouse model for rheumatoid arthritis. J Nucl Med (2013) 0.97
Facile labelling of an anti-epidermal growth factor receptor Nanobody with 68Ga via a novel bifunctional desferal chelate for immuno-PET. Eur J Nucl Med Mol Imaging (2011) 0.96
Nanobodies targeting the hepatocyte growth factor: potential new drugs for molecular cancer therapy. Mol Cancer Ther (2012) 0.96
Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody. Nucl Med Biol (2012) 0.95
Engineered affinity proteins for tumour-targeting applications. Biotechnol Appl Biochem (2009) 0.95
Localization, mechanism and reduction of renal retention of technetium-99m labeled epidermal growth factor receptor-specific nanobody in mice. Contrast Media Mol Imaging (2010) 0.92
Camelid single-domain antibody-fragment engineering for (pre)clinical in vivo molecular imaging applications: adjusting the bullet to its target. Expert Opin Biol Ther (2013) 0.92
Molecular imaging of reduced renal uptake of radiolabelled [DOTA0,Tyr3]octreotate by the combination of lysine and Gelofusine in rats. Nuklearmedizin (2008) 0.92
Targeted radionuclide therapy with A 177Lu-labeled anti-HER2 nanobody. Theranostics (2014) 0.91
Improved tumor targeting of anti-HER2 nanobody through N-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabeling. J Nucl Med (2014) 0.91
Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with 111In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts. Eur J Nucl Med Mol Imaging (2011) 0.90
Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with (177)Lu-octreotate. Eur J Nucl Med Mol Imaging (2013) 0.90
Molecular design and optimization of 99mTc-labeled recombinant affibody molecules improves their biodistribution and imaging properties. J Nucl Med (2011) 0.89
Radioimmunotherapy of micrometastases: sidestepping the solid-tumor hurdle. J Nucl Med (1995) 0.87
Development of 177Lu-nanobodies for radioimmunotherapy of HER2-positive breast cancer: evaluation of different bifunctional chelators. Contrast Media Mol Imaging (2012) 0.86
The emerging role of new protein scaffold-based agents for treatment of cancer. Cancer Genomics Proteomics (2013) 0.85
Improvement of radioimmunotherapy using pretargeting. Front Oncol (2013) 0.85
Radium-223 dichloride: a review of its use in patients with castration-resistant prostate cancer with symptomatic bone metastases. Drugs (2014) 0.84
Amplification of DNA damage by a γH2AX-targeted radiopharmaceutical. Nucl Med Biol (2012) 0.83
Targeted radionuclide therapy. Cancers (Basel) (2011) 0.83
Dose-response effect of Gelofusine on renal uptake and retention of radiolabelled octreotate in rats with CA20948 tumours. Eur J Nucl Med Mol Imaging (2009) 0.83
Influence of DOTA chelator position on biodistribution and targeting properties of (111)In-labeled synthetic anti-HER2 affibody molecules. Bioconjug Chem (2012) 0.83
Alternative Non-Antibody Protein Scaffolds for Molecular Imaging of Cancer. Curr Opin Chem Eng (2013) 0.83
Molecular theranostics: a primer for the imaging professional. AJR Am J Roentgenol (2011) 0.83
The new golden era for radioimmunotherapy: not just for lymphomas anymore. Cancer Control (2013) 0.82
In vivo and in vitro studies on renal uptake of radiolabeled affibody molecules for imaging of HER2 expression in tumors. Cancer Biother Radiopharm (2013) 0.81
Generation and characterization of nanobodies targeting PSMA for molecular imaging of prostate cancer. Contrast Media Mol Imaging (2014) 0.79
Imaging and radioimmunotherapy of multiple myeloma with anti-idiotypic Nanobodies. Leukemia (2013) 0.77
Molecular imaging with macrophage CRIg-targeting nanobodies for early and preclinical diagnosis in a mouse model of rheumatoid arthritis. J Nucl Med (2014) 0.76
Specific targeting of atherosclerotic plaques in ApoE(-/-) mice using a new Camelid sdAb binding the vulnerable plaque marker LOX-1. Mol Imaging Biol (2014) 0.76
A versatile nanotrap for biochemical and functional studies with fluorescent fusion proteins. Mol Cell Proteomics (2007) 4.28
Targeting and tracing antigens in live cells with fluorescent nanobodies. Nat Methods (2006) 3.12
Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies. Proc Natl Acad Sci U S A (2006) 2.51
Single-domain antibody fragments with high conformational stability. Protein Sci (2002) 2.31
Modulation of protein properties in living cells using nanobodies. Nat Struct Mol Biol (2009) 2.15
ProteomeBinders: planning a European resource of affinity reagents for analysis of the human proteome. Nat Methods (2007) 2.04
Non-invasive quantification of the beta cell mass by SPECT with ¹¹¹In-labelled exendin. Diabetologia (2014) 2.00
Nanobodies targeting mouse/human VCAM1 for the nuclear imaging of atherosclerotic lesions. Circ Res (2012) 1.67
A camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme. Nature (2003) 1.66
Optimal dose of 18F-FDG required for whole-body PET using an LSO PET camera. Eur J Nucl Med Mol Imaging (2003) 1.63
General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold. J Biol Chem (2008) 1.60
Single-domain antibodies as building blocks for novel therapeutics. Curr Opin Pharmacol (2008) 1.57
SPECT and PET amino acid tracer influx via system L (h4F2hc-hLAT1) and its transstimulation. J Nucl Med (2004) 1.55
Efficient targeting of conserved cryptic epitopes of infectious agents by single domain antibodies. African trypanosomes as paradigm. J Biol Chem (2003) 1.54
Three camelid VHH domains in complex with porcine pancreatic alpha-amylase. Inhibition and versatility of binding topology. J Biol Chem (2002) 1.51
Increased tumor uptake of 3-(123)I-Iodo-L-alpha-methyltyrosine after preloading with amino acids: an in vivo animal imaging study. J Nucl Med (2002) 1.49
Dynamic bioluminescence imaging for quantitative tumour burden assessment using IV or IP administration of D: -luciferin: effect on intensity, time kinetics and repeatability of photon emission. Eur J Nucl Med Mol Imaging (2008) 1.46
Efficient cancer therapy with a nanobody-based conjugate. Cancer Res (2004) 1.46
Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT. J Nucl Med (2008) 1.45
Crystal structure of the intrinsically flexible addiction antidote MazE. J Biol Chem (2003) 1.45
Notch signaling as gatekeeper of rat acinar-to-beta-cell conversion in vitro. Gastroenterology (2009) 1.42
Testicular cell transplantation into the human testes. Fertil Steril (2013) 1.42
Identification of a universal VHH framework to graft non-canonical antigen-binding loops of camel single-domain antibodies. J Mol Biol (2005) 1.41
123I-2-iodo-tyrosine, a new tumour imaging agent: human biodistribution, dosimetry and initial clinical evaluation in glioma patients. Eur J Nucl Med Mol Imaging (2007) 1.38
Efficient tumor targeting by single-domain antibody fragments of camels. Int J Cancer (2002) 1.36
Single domain antibodies derived from dromedary lymph node and peripheral blood lymphocytes sensing conformational variants of prostate-specific antigen. J Biol Chem (2004) 1.28
Nanobodies as novel agents for cancer therapy. Expert Opin Biol Ther (2005) 1.26
Specific cell targeting with nanobody conjugated branched gold nanoparticles for photothermal therapy. ACS Nano (2011) 1.24
Antibody repertoire development in camelids. Dev Comp Immunol (2006) 1.23
Reduced global cooperativity is a common feature underlying the amyloidogenicity of pathogenic lysozyme mutations. J Mol Biol (2004) 1.21
Nanobody-based targeting of the macrophage mannose receptor for effective in vivo imaging of tumor-associated macrophages. Cancer Res (2012) 1.20
Experimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factor. Nat Med (2006) 1.20
Disulfide bond introduction for general stabilization of immunoglobulin heavy-chain variable domains. J Mol Biol (2008) 1.17
VHH, bivalent domains and chimeric Heavy chain-only antibodies with high neutralizing efficacy for scorpion toxin AahI'. Mol Immunol (2008) 1.15
Nanobodies and their potential applications. Nanomedicine (Lond) (2013) 1.14
Bioluminescence imaging: looking beyond the light. Trends Mol Med (2012) 1.12
SPECT imaging with 99mTc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression. Mol Imaging Biol (2008) 1.12
Minimum information about a protein affinity reagent (MIAPAR). Nat Biotechnol (2010) 1.10
Engineering camel single-domain antibodies and immobilization chemistry for human prostate-specific antigen sensing. Anal Chem (2005) 1.10
Improved quantification in single-pinhole and multiple-pinhole SPECT using micro-CT information. Eur J Nucl Med Mol Imaging (2009) 1.09
A bispecific nanobody to provide full protection against lethal scorpion envenoming. FASEB J (2010) 1.08
Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer. FASEB J (2011) 1.08
A case of convergence: why did a simple alternative to canonical antibodies arise in sharks and camels? PLoS Biol (2011) 1.07
Nanobodies as tools for in vivo imaging of specific immune cell types. J Nucl Med (2010) 1.07
Prostate-specific antigen immunosensing based on mixed self-assembled monolayers, camel antibodies and colloidal gold enhanced sandwich assays. Biosens Bioelectron (2004) 1.04
An S-layer heavy chain camel antibody fusion protein for generation of a nanopatterned sensing layer to detect the prostate-specific antigen by surface plasmon resonance technology. Bioconjug Chem (2004) 1.04
Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 Nanobodies for iPET imaging of HER2 receptor expression in cancer. J Nucl Med (2013) 1.03
Melanoma targeting with alpha-melanocyte stimulating hormone analogs labeled with fac-[99mTc(CO)3]+: effect of cyclization on tumor-seeking properties. J Biol Inorg Chem (2008) 1.02
Antigen binding and solubility effects upon the veneering of a camel VHH in framework-2 to mimic a VH. J Mol Biol (2005) 1.02
Time-course of contrast enhancement in spleen and liver with Exia 160, Fenestra LC, and VC. Mol Imaging Biol (2008) 1.02
High affinity nanobodies against the Trypanosome brucei VSG are potent trypanolytic agents that block endocytosis. PLoS Pathog (2011) 1.01
Strong in vivo maturation compensates for structurally restricted H3 loops in antibody repertoires. J Biol Chem (2005) 1.01
Generation and characterization of a functional Nanobody against the vascular endothelial growth factor receptor-2; angiogenesis cell receptor. Mol Immunol (2011) 1.00
Engineering a camelid antibody fragment that binds to the active site of human lysozyme and inhibits its conversion into amyloid fibrils. Biochemistry (2008) 1.00
Inhibition of firefly luciferase by general anesthetics: effect on in vitro and in vivo bioluminescence imaging. PLoS One (2012) 1.00
In vitro analysis and in vivo tumor targeting of a humanized, grafted nanobody in mice using pinhole SPECT/micro-CT. J Nucl Med (2010) 0.99
SPECT imaging of joint inflammation with Nanobodies targeting the macrophage mannose receptor in a mouse model for rheumatoid arthritis. J Nucl Med (2013) 0.97
Immuno-imaging using nanobodies. Curr Opin Biotechnol (2011) 0.97
Parallel selection of multiple anti-infectome Nanobodies without access to purified antigens. J Immunol Methods (2007) 0.97
Nanobody-coupled microbubbles as novel molecular tracer. J Control Release (2011) 0.95
In vivo disassembly of IV administered siRNA matrix nanoparticles at the renal filtration barrier. Biomaterials (2012) 0.95
Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody. Nucl Med Biol (2012) 0.95
Identification of potent nanobodies to neutralize the most poisonous polypeptide from scorpion venom. Biochem J (2009) 0.95
Chemical basis for the affinity maturation of a camel single domain antibody. J Biol Chem (2004) 0.94
Evaluation of the radiation dose in micro-CT with optimization of the scan protocol. Contrast Media Mol Imaging (2010) 0.94